ASK REDCHAT ANYTHING ABOUT ATAI LIFE SCIENCES N.V.
ATAI Life Sciences N.V. (NASDAQ: ATAI)
Listen to this Section
$4.07
-0.4350
(
-9.67% )
4.2M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| COMP360DetailsTreatment Resistant Depression |
Phase 3 |
| RL-007DetailsCognitive Dysfunction, Schizophrenia |
Phase 2b |
| BPL-003 (Intranasal 5-MeO-DMT)DetailsTreatment Resistant Depression |
Phase 2b |
| VLS-01DetailsTreatment Resistant Depression |
Phase 2 |
| COMP360DetailsPost-traumatic stress disorder |
Phase 2 |
| GRX-917DetailsAnxiety Disorders |
Phase 2 |
| ELE-101DetailsMajor depressive disorder |
Phase 2a |
| BPL-003 (Intranasal 5-MeO-DMT)DetailsAlcohol use disorder |
Phase 2a |
| Ibogaine (DMX-1002)DetailsOpioid use disorder |
Phase 1/2 |
| EMP-01 (3,4-methylenedioxy-methamphetamine [MDMA] derivative)DetailsSocial Anxiety Disorder, Mental health |
Phase 1 |
| PCN-101 (R-Ketamine)DetailsTreatment Resistant Depression |
Phase 1 |
| PCN-101DetailsTreatment Resistant Depression |
Failed |
Market Data
|
| Open |
$4.07 |
| Previous Close |
$4.50 |
| Volume |
4.2M |
| Market Cap |
$1.67B |
| Day Range |
$4.01 - $4.55 |
| 52 Week Range |
$2.00 - $6.75 |
| Shares Outstanding |
368.17M |
| Change % |
-9.67% |
| Net Change |
▼ -0.4350 |
| Insider Ownership |
-1.06% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2021 |
| Country | Germany |
| Underwriter | Credit Suisse, Citi, TD Cowen, Berenberg, Cantor Fitzgerald, RBC Capital Markets, Canaccord Genuity, more |
Insider Ownership Transactions
Total Amount Purchased:
18,024,196.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-04-17 |
Sale |
-147950.00 |
Apeiron Investment Group Ltd. |
| 2024-04-04 |
Sale |
-35801.00 |
Kirpekar Sahil |
| 2024-04-04 |
Sale |
-61640.00 |
Rao Srinivas |
| 2024-04-04 |
Sale |
-27410.00 |
Johnson Anne Nagengast |
| 2024-03-15 |
Sale |
-175000.00 |
Rao Srinivas |
| 2024-03-15 |
Sale |
-350000.00 |
Brand Florian |
| 2024-03-15 |
Sale |
-100000.00 |
Kirpekar Sahil |
| 2024-03-15 |
Sale |
-100000.00 |
Johnson Anne Nagengast |
| 2024-03-12 |
Buy |
7401.00 |
ATAI Life Sciences N.V. |
| 2024-01-09 |
Sale |
-642000.00 |
Angermayer Christian |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 8-k |
8K-related |
14 |
Dec 05, 2025 |
| 4 |
Insider transactions |
1 |
Nov 26, 2025 |
| 8-k |
8K-related |
14 |
Nov 12, 2025 |
| 10-q |
Quarterly Reports |
126 |
Nov 12, 2025 |
| 3 |
Insider transactions |
2 |
Nov 06, 2025 |
| 4 |
Insider transactions |
1 |
Nov 06, 2025 |
| 4 |
Insider transactions |
1 |
Nov 06, 2025 |
| 4 |
Insider transactions |
1 |
Nov 06, 2025 |
| 3 |
Insider transactions |
2 |
Nov 06, 2025 |
| 8-k |
8K-related |
14 |
Nov 05, 2025 |